Pulse Biosciences, Inc $PLSE Stock Sold by Inspire Investing LLC

Inspire Investing LLC cut its stake in Pulse Biosciences, Inc (NASDAQ:PLSE) by 46.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,773 shares of the company’s stock after selling 11,246 shares during the period. Inspire Investing LLC’s holdings in Pulse Biosciences were worth $638,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of PLSE. Bank of America Corp DE grew its position in Pulse Biosciences by 8.2% in the first quarter. Bank of America Corp DE now owns 866,061 shares of the company’s stock valued at $18,698,000 after acquiring an additional 65,884 shares during the period. Deutsche Bank AG acquired a new position in Pulse Biosciences during the second quarter worth $687,000. Panoramic Capital LLC acquired a new position in Pulse Biosciences during the second quarter worth $2,719,000. BlackRock Inc. bought a new position in shares of Pulse Biosciences during the second quarter valued at $40,672,000. Finally, Formula Growth Ltd. bought a new position in shares of Pulse Biosciences during the second quarter valued at $832,000. Institutional investors own 76.95% of the company’s stock.

Insiders Place Their Bets

In related news, COO Liane Teplitsky bought 1,001 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was bought at an average cost of $49.95 per share, with a total value of $49,999.95. Following the completion of the purchase, the chief operating officer owned 4,095 shares in the company, valued at approximately $204,545.25. The trade was a 32.35% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last ninety days, insiders have bought 4,095 shares of company stock valued at $199,931. Company insiders own 74.00% of the company’s stock.

Pulse Biosciences Stock Performance

Shares of NASDAQ:PLSE opened at $53.67 on Thursday. Pulse Biosciences, Inc has a twelve month low of $12.56 and a twelve month high of $58.90. The firm has a market cap of $3.80 billion, a PE ratio of -45.48 and a beta of 1.57. The business has a fifty day moving average of $50.82 and a 200-day moving average of $30.89.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The business had revenue of $0.43 million during the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. On average, analysts anticipate that Pulse Biosciences, Inc will post -1.34 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on PLSE shares. BTIG Research began coverage on shares of Pulse Biosciences in a research note on Wednesday, September 23rd. They issued a “buy” rating and a $70.00 target price on the stock. Canaccord Genuity Group increased their target price on shares of Pulse Biosciences from $43.00 to $58.00 and gave the stock a “buy” rating in a research report on Tuesday, October 6th. Freedom Capital upgraded shares of Pulse Biosciences to a “strong-buy” rating in a research report on Wednesday, September 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, October 15th. Finally, Needham & Company LLC assumed coverage on shares of Pulse Biosciences in a report on Monday, August 17th. They set a “buy” rating and a $58.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $60.20.

Pulse Biosciences Profile

Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.